Skip to main content
. 2022 May 3;13:842453. doi: 10.3389/fimmu.2022.842453

Figure 1.

Figure 1

Therapeutic mechanisms of exogenous pulmonary surfactant for SARS-CoV-2 infection. Pulmonary surfactant can (1) mitigate acute respiratory distress syndrome by reducing alveolar surface tension and improving pulmonary mechanical properties; (2) suppress pro-inflammatory cytokine secretion; and (3) potentially inhibit SARS-CoV-2 replication and restrict SARS-CoV-2 infection.